Dean Li, MD, PhD, is the Vice President and Head of the Translational Medicine Department at Merck. He was previously the Chief Scientific Officer, Associate Vice President and Vice Dean at the University of Utah Health System. Dean is co-founder of three biotechnology companies (Hydra Biosciences, Navigen Pharmaceuticals, Recursion Pharmaceuticals) each built around platforms and products developed in his academic laboratory that study signaling pathways critical to vascular dysplasia, cancer and inflammation. Dean is a cardiologist and a member of the American Society of Clinical Investigation and the Association of American Physicians. Dean received his medical and graduate degrees and his clinical training at Washington University School of Medicine in St. Louis.